Jim Cramer continues to show his support for the biotech company, as evident by his most recent comments from the 14 th of ...
We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...
Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Zacks Investment Research on MSN4d
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to KnowIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback